Introduction: Over the last year, multiple,
Selection criteria were trials of broad relevance to the cardiology community, those with potential to change current practice and those with potential to guide further phase III research. Results: In this paper, the authors describe and place in clinical context, new HF, data including neprilysin inhibitors, intravenous ferric carboxymaltose, potassium-absorbing compounds, quadripolar leads for cardiac resynchronization therapy and intraventricular device intervention. New trial data are also described for acute coronary syndromes (clopidogrel, prasugrel, ticagrelor) [3] . In this study, 304 HF patients (defined as LV ejection fraction\45%, NYHA II-III), with increased brain natriuretic peptide and serum ferritin \100 ng/mL (or 100-300 ng/mL if transferrin saturation was \20%) were randomized to intravenous Fig. 1 The primary end point of cardiovascular death or HF hospitalization taken with permission from PARADIGM-HF. Reproduced with permission from [2] . HR hazard ratio ferric carboxymaltose or placebo given at time points of baseline, 6, 12, 24, and 36 weeks. The trial's primary end point, the 6-minute walk test duration at 24 weeks, was significantly improved in the intravenous iron group (33 m greater distance; p = 0.002), as were the secondary outcomes of NYHA class, fatigue score, quality of life scores, and self-reported patient global health assessment (p\0.05 for all). Treatment with intravenous iron was also associated with a significant reduction in the risk of HF hospitalizations [HR 0.39 (95% CI 0.19-0.82); p = 0.009]. The study was not powered to detect difference in mortality. In keeping with previous studies, CONFIRM HF supports iron treatment in HF patients with low ferritin.
A recurrent concern of HF patients is the presence of hyperkalemia. Reasons for this include concomitant renal failure and the use of drugs such as renin-angiotensin-aldosterone inhibiting agents and aldosterone antagonists.
A potassium-absorbing compound, patiromer, was used in a two-phase trial, with hyperkalemic patients randomized to either placebo or this new drug with the dose depending on their initial serum potassium [4] . In the initial single-blind phase of the study, 102 patients with HF and 141 without received patiromer at two different dosage levels. Compared with placebo, there was a sustained decrease in serum potassium, both in patients with (p\0.001) and without (p\0.001) HF. The second phase of the study looked at patients who had received patiromer and who were taking a renin-angiotensinaldosterone inhibiting agent. In this phase, 107 patients whose initial potassium was [5.5 to \6.5 mEq/L and subsequently decreased to 3.8 to\5.5 mEq/L were randomized to continue patiromer (n = 55) or to switch to placebo (n = 52) and were followed for another 8 weeks. Switching patiromer to placebo led to a significant increase in potassium compared with maintenance, both in patients with (n = 49) and without (n = 58) HF, with potassium levels C5.5 mmol/l occurring in 60% of the patients in the placebo group as compared to only 15% in the patiromer group (p\0.001). Given these encouraging findings, further study with patiromer is planned including evaluation of the impact on overall clinical outcomes.
After an anterior wall myocardial infarction [7] reported that the severity of stenosis in nonculprit arteries was associated with future risk of subsequent clinical events [10] . Patients with an operator-determined 95-99% stenosis had a 47% incidence of major adverse cardiac events (MACE), whereas patients with 75-94% stenosis and 50-74% stenosis had a 23% and 14% incidence of MACE, respectively. Although CVLPRIT was relatively small and there were no significant differences in mortality or HF (MACE difference being driven by soft end point of revascularization), along with PRAMI, it supports an interventional rather than conservative approach to non-culprit lesions. This is in contrast to a meta-analysis of 34,279 patients published earlier in 2014, which suggested that there was no significant difference in hospital mortality with multivessel PCI vs. culprit-only PCI [11] .
Further prospective data are still required, which may be provided by the Complete vs.
Culprit-only Revascularization to Treat Multivessel Disease After Primary PCI for STEMI (COMPLETE) study (ClinicalTrials.gov #NCT01740479) which is a large ongoing trial comparing staged non-culprit PCI with conservative treatment [12] .
The Thrombus Aspiration in ST-Elevation
Myocardial Infarction in Scandinavia (TASTE) trial (ClinicalTrials.gov #NCT01093404) presented its primary outcome (30 day mortality rates) at the 2013 ESC conference [13] , and full 1-year results were presented at ESC 2014 [14] . This large, randomized, registry trial allocated 7244 patients to manual thrombus aspiration followed by PCI versus PCI only. There was no significant difference between the two groups in all-cause mortality at (ClinicalTrials.gov #NCT00389220) and warrants further study [17] . Family Heart Study was an important study in over 22,000 adolescents and children aged 3-18 years old [20] . Levels of BP were recorded and compared to the markers of obesity such as body mass index, waist circumference, waist-to-height ratio, percentage of body fat, and skinfold thickness. Pre-hypertension was defined as a BP between the 90th and 95th percentile of the BP curve for children and adolescents, while hypertension was a BP reading over the 95th percentile. The prevalence of hypertension was 5.4% in normal weight, 9.8% in overweight and 21.5% in obese subjects. Unsurprisingly, the presence of obesity strongly correlated with hypertension-obese boys having an odds ratio (OR) of 5.9 and obese girls 4.3. Compared with normal weight subjects, the risk of having pre-hypertension was significantly raised in overweight males and females (OR 1.6 and OR 1.8, respectively) and obese males and females (OR 2.4 and OR 3.3, respectively). This study highlights the dangers of childhood obesity.
Hypertension

Antiplatelet Therapy
The optimum duration of dual antiplatelet therapy (DAPT) following coronary stenting or acute coronary syndrome has been assessed in several large studies during 2014. The DAPT study (ClinicalTrials.gov #NCT00977938) presented at AHA 2014 randomized 9961 patients who had received a drug-eluting stent (DES) and 12 months of DAPT to aspirin only for a further 18 months (30 in total) of DAPT [21] . Those [22] . There was no significant difference between the two groups in the incidence of the primary composite end point (cardiac death, MI, stroke, definite or probable stent thrombosis or Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 12 months) occurring in 4.5% vs. 3.7% of patients, respectively; p = 0.469).
There was also no difference in the incidence of definite or probable stent thrombosis at Unadjusted MACE rates (a composite of death, MI, stroke, or unplanned revascularization) were higher with clopidogrel than prasugrel (17.3% vs. 13.5%; p\0.0001). However, patients receiving prasugrel were more likely to be younger, male, or presenting with STEMI and less likely to have had a history of prior MI, coronary artery bypass graft (CABG), or stroke/transient ischemic attack. After adjustment for baseline population differences, there was no longer any difference in overall MACE, although clopidogrel was associated with a higher risk of stent thrombosis but a lower risk of bleeding in keeping with previous randomized data. [32, 33] .
Anticoagulation
Stable Coronary Artery Disease
Previous subgroup analysis suggested that the sino-atrial node-blocking agent ivabradine may improve outcomes in patients with stable coronary artery disease and a heart rate of 70 beats per minute or more, especially among those with limiting angina [34] . Ivabradine, which was at doses up to 10 mg twice a day (higher than currently licensed), was associated with a marked increase in bradycardia (18.0% vs. 2.3%; p\0.001). While heart rate lowering remains of symptomatic value for stable angina, this important and wellconducted trial challenges the commonly held view regarding prognostic benefit. In particular, excessive heart rate lowering may be disadvantageous.
The value of invasive fractional flow reserve (FFR) assessment of moderate coronary stenoses is gaining increasingly wide clinical acceptance. Medical Therapy alone (FAME II) trial (ClinicalTrials.gov #NCT01132495), stable patients (n = 1220) scheduled for elective PCI first underwent pressure wire assessment for FFR [37] . Those patients (n = 888) with at least one Although there were no significant differences in the rates of death and MI overall, in a landmark analysis the rate of death or MI from 8 days to 2 years was lower in the PCI group than in the medical therapy group (4.6% vs.
8.0%; p = 0.04). Of note, the use of PCI reduced event rates similar to that seen in the registry of patients with non-obstructive disease (FFR [0.80) in whom the primary end point was 9.0% at 2 years.
Arrhythmias and Devices
Cardiac resynchronization therapy (CRT) has been proven to improve HF symptoms and outcomes in patients with LV dysfunction and a broad QRS complex on electrocardiography [38, 39] . However, failure to implant an LV lead occurs in approximately 5-15% of cases [40, 41] Antiplatelet treatment was only associated with a non-significant reduction of stroke and death. Both treatments carried a small non-significant adjusted incidence of major bleeding. This study supports the association of asymptomatic AF with adverse outcomes, which may be reduced by oral anticoagulant but not antiplatelet treatment.
An interesting, yet small study presented at the ESC 2014 by Anguera et al. [46] (Fig. 4) , driven by a significant reduction in MI (14.8% vs. 13.1%; p = 0.002) and ischemic stroke (4.1% vs. 3.4%; p = 0.008) ( [47] . CHD coronary heart disease, Cor revasc coronary artery revascularization, CVD cardiovascular disease, EZ ezetimibe, HR hazard ratio, MI myocardial infarction, Simva simvastatin, UA unstable angina Reproduced with permission from [47] . CI confidence interval, EZ ezetimibe, HR hazard ratio, NNT numbers needed to treat, Simva simvastatin 
